Articles
🇺🇸 AmericasExpert insights, opinion pieces, and in-depth analysis on pharmaceutical trends and FDA regulations.
Understanding Computer Software Assurance (CSA) and Its Benefits for Pharma
Computer Software Assurance (CSA) is the FDA's updated, risk-based approach to validating software used in production and quality systems, shifting from traditional, documentation-heavy methods. This new framework emphasizes critical thinking and focuses on patient safety and product quality, offering significant benefits to pharmaceutical companies.
FDA Oncology Draft Guidance: Reducing Animal Testing for Cancer Drugs
The FDA has issued draft guidance aimed at reducing unnecessary animal testing in oncology drug development. This initiative supports expedited pathways for novel treatments while aligning with the agency's commitment to animal welfare.
Cumberland Pharmaceuticals (NASDAQ: CPIX) to divest marketed brands to Apotex for $100M
Structured plan for Cumberland Pharmaceuticals (NASDAQ: CPIX) to divest marketed brands to Apotex for $100M
Private Equity Healthcare Policy Agenda Guide
Private equity's rapid expansion in the healthcare sector has outpaced current regulatory frameworks. This article outlines a strategic policy agenda necessary to safeguard patients, providers, and the integrity of care delivery.
OhioHealth and Fairfield Medical Center Terminate Merger Plans
OhioHealth and Fairfield Medical Center have officially terminated their proposed merger plans, a development that alters the landscape of healthcare provider news in Ohio. The initial announcement of the acquisition proposal was made last November.
Kardigan's IPO Plans: Fueling the Next Wave of Cardiovascular Drug Development
Cardiovascular drug developer Kardigan is gearing up for an IPO on the Nasdaq Global Market to finance the late-stage development of its pipeline, including danicamtiv for genetic dilated cardiomyopathy. This move signals a potential uptick in biotech IPOs as the market becomes more discerning.
Top Biotech Penny Stocks to Watch in 2026: A Strategic Outlook
Identifying promising biotech penny stocks under $1 for 2026 requires a deep dive into pipeline potential and market dynamics. This article highlights key companies poised for significant growth.
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
Biotech stocks showed mixed performance as Moderna advanced its Ebola vaccine efforts and Summit Therapeutics saw a surge on Phase 3 data. Meanwhile, Alignment Healthcare faced a downgrade, and Iovance Biotherapeutics remains a subject of analyst debate.
FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer
Structured plan for FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
Gilead Sciences has achieved a significant milestone with the FDA approval of bulevirtide, the first drug to treat chronic hepatitis D. This landmark decision intensifies the competitive landscape as Bay Area rivals Vir Biotechnology and Mirum Pharmaceuticals advance their own therapies.
FDA Approves MannKind's Afrezza for Pediatric Diabetes Patients
The US FDA has approved MannKind's Afrezza inhaled insulin for pediatric patients aged 6 and older diagnosed with Type 1 or Type 2 diabetes. This approval marks a significant expansion for the inhaled insulin.
Elite Pharma ANDA Filing for Anticoagulant
Structured plan for Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
FDA OK for Pivekimab Sunirine-pvzy (Decnupaz)
The US FDA has approved AbbVie's antibody-drug conjugate, Decnupaz (pivekimab sunirine-pvzy), for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks AbbVie's first ADC entry in the blood cancer space and the first ADC approval for this ultra-rare indication.
Lilly 340B Data Mandate: Hospital Discount Fight
Eli Lilly has issued a five-day ultimatum to over 1,000 hospitals, requiring them to submit claims data or risk losing access to 340B drug discounts. This move signals a significant escalation in the ongoing conflict between pharmaceutical manufacturers and healthcare providers over the controversial program.
Eli Lilly's Retatrutide Success Amidst Regulatory Shifts: A Strategic Analysis
Eli Lilly's triple agonist, retatrutide, has achieved a significant Phase 3 win, demonstrating substantial weight loss. This success occurs against a backdrop of notable regulatory changes, impacting the pharmaceutical landscape.
Childhood Vaccine Schedule EO: Pharma Impact
President Trump has signed an executive order initiating an overhaul of the childhood vaccine schedule, signaling potential shifts in public health policy. This move could have significant implications for pharmaceutical companies involved in vaccine development and manufacturing.
Servier $2.65B Muscular Dystrophy Asset Deal
French pharmaceutical giant Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for an upfront payment of $1.55 billion, with potential milestone payments reaching up to $2.7 billion. This strategic move significantly expands Servier's footprint in the rare disease and neurology space.
ASCO 2026: Key Takeaways on Cancer Care Barriers and New Treatments
The ASCO 2026 meeting highlighted critical barriers to effective cancer care and showcased promising new treatment modalities. Key takeaways offer insights into the evolving landscape of oncology drug development and patient access.
CEPI Funds Three Ebola Vaccine Candidates to Accelerate Outbreak Response
A global coalition, led by CEPI, has allocated $62 million to fast-track the development of three experimental Ebola vaccines. This significant investment aims to expedite the availability of crucial tools for combating future Ebola outbreaks.
Candel's Prostate Cancer Drug: Long-Term Data Insights Ahead of FDA Filing
Candel Therapeutics is poised to file its prostate cancer drug, CAN-2409, with the FDA following positive long-term Phase 3 data. This analysis explores the clinical and commercial implications for the pharmaceutical industry.